Ellex Medical Lasers (ASX:ELX) has announced that it has secured a patent agreement which will allow it to launch its Ellex 2RT retinal laser treatment in the US.
The company has entered into a sublicense agreement with a US medical laser research institute for the selected laser targeting of pigmented optical cells.
This patent had previously prevented Ellex from selling its product in the US,, although the company has filed four international patents related to Ellex 2RT.
“The next phase of the Ellex 2RT program will focus on undertaking further clinical trials, and on obtaining key regulatory approvals for the Ellex 2RT product range,” Ellex CEO Simon Luscombe said.
Join the CIO Australia group on LinkedIn. The group is open to CIOs, IT Directors, COOs, CTOs and senior IT managers.